 | The global pain management market continued to demonstrate double digit growth figures in 2007, despite patent expiries of leading products and strong generic competition. The intricacy of pain pathways has added to the complexity of this pathological condition, which mostly requires symptomatic treatment. Additionally, few classes of drugs are specifically indicated in management of pain, such as non–steroidal anti–inflammatory agents, local anesthetics and analgesics. The use of other classes of drugs such as anticonvulsants, mostly in adjuvant therapy, is based on medical requirements. This new report from Business Insights gives a strategic insight into the pain management market, its structure based on drug classes, and the relative positioning of leading players. |
|
| Establishing the most effective route to exit for a biotech venture is critical in ensuring value is maximized for key stakeholders and the associated technology. However, more critical than selection of exit strategy is the planning and effective execution of exit. Fledgling biotech companies owe their existence to the promise of a valuable exit for the early-stage funder. As a result, each and every biotech company must be able to demonstrate that all plans and actions are effective steps towards the realization of success exit, even where the method and timing of exit are largely undecided. ‘Biotech Exit Strategies’ report provides a detailed review of current and future trends in biotech exit strategies and uses real-life case studies to illustrate the key challenges and critical success factors involved in executing an exit for biotech investors. The report provides a unique strategic analysis for successfully dealing with the prevailing challenging financial conditions facing biotech companies and investors. |
|
| The US healthcare system involves a multitude of stakeholders; a mix of public and private players. The government funds healthcare for certain sections of the society while majority of the population has a private health insurance sponsored by employers. Pharmaceutical manufacturers in the US are relatively free to set their own prices for drugs which tend to be, on an average, two to three times higher than in Europe. The US market in general works by administering reimbursement controls rather than price controls. Instead of a direct price control, the government is known to have been using tacit persuasion tactics, on grounds of morality, to convince drug companies to slash prices. However the scenario is changing in light of a growing demand for administering direct price controls. The report provides analysis on the performance of key brands in a range of major indications in the US pharmaceutical market, including central nervous system disorders, cancer, cardiovascular diseases and metabolic disorders. The report also incorporates analysis of the portfolios and pipelines of the leading pharmaceutical companies active in the US market today. |
|
| Cardiovascular diseases and metabolic disorders are the most common groups of disease in Eastern Europe. Moreover, poor housing standards have exacerbated the spread of communicable diseases such as tuberculosis, diphtheria and cholera. In Eastern European countries, the rising expenditure on prescription pharmaceuticals is the leading contributor to increasing pressure on healthcare finances, and has therefore been a major catalyst for healthcare reforms. The Eastern European Pharmaceutical Market Outlook to 2014 provides a comprehensive coverage of the Eastern European pharmaceutical market, reviewing the market structure, pricing and regulation and includes detailed epidemiological analyses of the common indications. This report makes a wide-ranging assessment of the marketed product portfolio, R&D pipeline, market share data, sales forecast and competitive landscape for the major players in Eastern European market. |
|
| The pharma outsourcing industry in China has experienced over 35% year on year growth in the past few years. Increasingly, the sophisticated service offer of multinational CROs/CMOs is being challenged by improving Chinese players importing Western expertise, experience and business models to this fast growth market. However, there are still wide variations in service quality and capability from domestic outsourcing providers and many pharma and biotechs in Western markets are still reluctant to transfer parts of the drug development process to China. |
|
| The emerging global market for biosimilars market grew 5.9% to reach a value of approximately $1bn in 2007. In the near term, four drug classes including erythropoietin, filgrastim, human growth hormone (hGH) and insulin, will drive the growth of biosimilars. Based on 2007 sales reported by IMS, biologics worth $25bn are expected to go off-patent by 2016, thus creating a significant market opportunity for biosimilars. This report provides an overview of the global biosimilars market, including its size, various business strategies adopted by the top 10 companies, current industry trends and future opportunities. It also discusses the biosimilars approval process in the US, EU and major semi-regulated markets. This report ranks the top 10 companies based on their sales in the 1H 2008 and maps their marketed and pipeline products across the off-patent biologics categories. It also highlights the factors that will either drive or inhibit the growth of biosimilars. |
|
 | Quintiles leads the global CRO market having accrued a market share of 16.9% in 2007, equivalent to sales of $2.7bn. There are over 1,100 players in the industry, and the top 10 players only accounted for 56.1% of the global market in 2007. |
|
 | Biobanks collect and store human biospecimens, playing a vital role in the development of novel drugs and diagnostics. In recent years, large population-based biobanks have been established which monitor the health status of participants over time to assess the natural occurrence and progression of common diseases. Hundreds of disease-based biobanks are located around the world, which are a valuable resource for biomarker discovery as well as for studying progression, mortality and responses to treatment. ‘The Future of Biobanks’ is a new report published by Business Insights that examines major trends in the biobanking industry and identifies the key initiatives to upgrade the biobanking infrastructure. This report explores the applications of biobanks and provides examples of how large sets of high-quality biosamples are creating new ways to diagnose, prevent and treat diseases. The activities of over 180 US biobanks are assessed to illustrate how the scale and scope of biobanking is changing. This report also evaluates the limitations of biobanks, in addition to reviewing the unique legal, regulatory and ethical issues that surround this new frontier of biomolecular research. |
|
| The Autoimmune Market Outlook to 2013 provides comprehensive coverage of the autoimmune market, incorporating disease overviews and detailed epidemiological analyses for the major indications. This report makes a comprehensive assessment of the marketed product portfolio, R&D pipeline, market share data, sales forecast and the competitive landscape for the major players. Further, this report highlights the key market and R&D trends that may influence drug sales, with a thorough analysis of the competitive dynamics of leading brands within each indication to enable you to identify growth brands, key drug classes and leading players through to 2013. |
|
| The Asian cardiovascular market demonstrated robust sales, unlike the global market which has begun to slow down due to patent expiries of class leading products and strong generic competition. The emerging ten Asian markets analyzed in this report is a mixture of developed nations like South Korea, Taiwan, Hong Kong, Singapore and Malaysia, and developing markets such as China, India, Thailand, Philippines and Indonesia. Although these markets have lower healthcare expenditure per head compared to the US and EU, the Asian markets are regarded as the potential growth markets of the health services industry and consequently the pharmaceutical sector. The market is also being driven by the shift of focus from primary care to specialty care. In comparison to the western markets drug patent expiries minimally affect proprietary brand growth dynamics in Asia. Regional customization of brand prices and aggressive marketing strategies have positioned branded drugs in direct competition with generic brands. |
|
| This report provides comprehensive coverage of the Canadian market, incorporating an overview of the country, its socioeconomic status and the epidemiological scenario of major pathophysiological disorders. Furthermore, the report analyzes the scenario in Canada pertaining to pharmaceutical regulation, pricing and reimbursement. Finally, the report analyzes the marketed product portfolios, R&D pipelines and market share data of the leading pharmaceutical companies in Canada, and provides sales forecasts. |
|
| The Scandinavian healthcare system and pharmaceutical market is well regulated with the state bearing responsibility for a large proportion of an individual’s pharmaceutical expenses. Solidarity and equality being the ideological basis of these welfare states, a significant public commitment exists towards ensuring access to high quality health care for all citizens. Whilst doctors make the choice of the medication, the authorities pay the cost of these drugs, insuring citizens against large drug expenses. The public sector bears this cost of pharmaceuticals either directly through hospitals or by providing reimbursement to patients. Pharmaceutical price regulation comes into play not just at the point of sale to the final consumer but at all parts of the distribution chain. Price regulation also varies depending on whether the drug is a patent protected prescription drug or a prescription drug facing generic competition or a non-prescription drug. The prevalence of parallel trade further shapes the dynamics of the pharmaceutical market in the Scandinavian region, while also affecting the states’ expenditure on health. Incentives existing for patients and pharmacists to switch to a lower priced product drive savings from parallel trade. In Sweden for instance, the state is able to generate significant savings as parallel imports are considered substitutable products under the generic substitution policy and pharmacists are required to always dispense the cheapest of alternative products. |
|
 | This report provides a detailed analysis of licensing strategies in the biopharmaceutical industry over the 2001-08 period and draws upon the growth of the biopharmaceutical industry, deal-making trend data, drivers and challenges facing biopharmaceutical licensing, and profiles of biopharmaceutical licensing among leading companies. Building upon this, the report examines the future prospects of the Biopharma industry and how current market and political/regulatory factors will impact the dynamics of licensing and alliances, as well as potential strategies for sustaining growth. This report also looks at the recent upsurge in M&A activity and potential scenarios of how Biopharma will be impacted and recommendations on strategies the industry should employ to sustain future growth. |
|
| Technology transfer is a long-established part of early-stage research within the pharmaceutical and biotechnology industries. Although technology transfer offices have traditionally been associated with inefficiency and a lack of commercial judgment, recent trends have shown improvements in staffing, expertise and service levels. However, the tech transfer function has recently suffered from ‘funding gaps’ for promising new technologies. A clear disparity exists between current service offerings and demand levels amongst investors/industry partners, while the lack of an established model for effective technology transfer function and significant regional variations are major obstacles to future progress. ‘Technology Transfer Strategies’ is a new, uniquely themed report published by Business Insights that provides a comprehensive examination of the major trends in technology transfer activity in the US, Canada and Europe. The report provides a detailed country-level analysis of technology transfer and associated intellectual property technology regulations, in addition to evaluating the key approaches to office structuring and strategies to negotiate the ’funding gap’. A series of in-depth interviews also document the experiences and insights of 11 tech transfer experts, and their recommendations for successful technology transfer strategies are revealed. |
|
| As regulatory obstacles to biosimilars development have become increasingly resolved, a growing number of opportunities have been created for generics companies in the biopharmaceutical market, which is forecast to value in excess of $135 billion by 2011. In response, the originators of biopharmaceutical products are resorting to a range of defensive tactics, including the reformulation of existing products to improve efficacy, the implementation of more efficient delivery systems and the pursuit of intellectual property battles. 'Negotiating the Emerging Biosimilars Landscape' is a new report published by Business Insights that examines the structure of the biopharmaceutical industry and the strategic approaches taken to alleviate the threat posed by the biosimilar market. The key factors affecting market access within the biosimilars market are assessed and the latest issues surrounding bioequivalence are examined. This report also provides a comprehensive review of the current legislative and regulatory positions of key geographic regions in addition to evaluating their anticipated future legislative changes and outcomes. |
|
 | Emerging drug delivery technologies aim to improve measures of safety, efficacy, convenience and compliance in both new and existing drug candidates and products. For currently marketed products, reformulations with new delivery technologies will extend the period of patent protection. New formulas will be key to boosting sales volume of large molecule products in chronic diseases where patient compliance surrounding dosing strategies and ease of administration are limitations on market growth. In R&D pipelines, novel applications of delivery technologies will expose new methods to reformulate failed or discontinued drugs and mask their unfavorable effects, expanding the market of potential drug candidates. ‘Delivery Mechanisms for Large Molecule Drugs’ is a new report published by Business Insights that examines the future of the drug delivery technologies market, and the short, mid, and long-term growth dynamics which will underpin investment decisions. This report will measure the performance of leading drug delivery technologies applied within clinical R&D pipelines and identify when specific therapy area populations are set to benefit from emerging innovations. The market success of new technologies is forecast by their ability to fulfill unmet medical need, the maturity of the technology in clinical application, and the level of commercial interest and investment landscape. |
|
 | The cardiovascular therapy area spans a range of treatment classes including anti-hypertensives, anti-dyslipidemics, anti-thrombotics, hematological preparations and cardiac therapies. Each sub-therapy area is facing a different set of issues and challenges, such as the current generic threat for dyslipidemics and competition from novel therapies in thrombosis. Leading products in these sub-therapy areas have proven to be significant growth drivers for Big Pharma, such as Pfizer’s Lipitor, Sanofi’s Plavix and Lovenox, and Amgen’s Aranesp. The recent emergence of smaller players and increased competition from generics has prompted leading players to engage in alliances and agreements for key drugs to keep pace with the changing market landscape. ‘The Cardiovascular Market Outlook to 2013: Competitive landscape, global market analysis and pipeline analysis’ is a new report published by Business Insights that provides comprehensive coverage of every class of drugs across major cardiovascular indications. Detailed insights into recent key events and future market leaders are also provided, in addition to epidemiological analysis and forecasts for major products over the 2007-13 period. With coverage of over 90% of the total market for cardiovascular products, this report profiles the underlying trends and factors driving the market and identifies the most promising areas of potential growth. Discover the key market trends and growth drivers of the cardiovascular market, assess the competitive dynamics of leading companies and evaluate the future prospects of major products with this new report.Published: January 2009 - Global. |
|
| The Cancer Market Outlook to 2013 provides comprehensive coverage of the cancer market, incorporating the disease overview and detailed epidemiological analyses of the major indications. This report makes a comprehensive assessment of the marketed product portfolio, R&D pipeline, market share data, sales forecast and the competitive landscape for the major players. Further, this report highlights the key market and R&D trends that may influence treatment sales, with a thorough analysis of the competitive dynamics of leading brands within each indication to enable you identify growth brands, key drug classes and leading players through to 2013. |
|
| The pharmaceutical industry is facing many challenges to which it must respond to in the next 10 years if it is going to sustain the sales growth that it has achieved in the past 10 years. The most pressing of these problems is the falling level of R&D productivity with the number if NMEs being approved by the FDA having steadily decreased since 1996. This problem is compounded by the number of blockbuster drugs losing patent protection and facing generic competition as a resultPublished: November 2008 - Global. |
|
| Specialty pharmaceutical companies focus the majority of their efforts upon one or two therapeutic areas that are served by specialized physicians. Their traditional mode of operation is to acquire under-promoted branded products from Big Pharma companies that are generating lower sales and significantly increase revenues through the application of targeted marketing and promotional activities. However, the dynamics of the industry are changing. Rising costs for in-licensing and acquiring late stage/approved products have driven companies to develop products internally in order to remain competitive. ‘The Top Ten Specialty Pharmaceutical Companies’ is a new report published by Business Insights that explores the global competitive landscape of the specialty pharmaceutical industry. The latest key trends and evolving business models in the specialty pharmaceutical market are identified and the leading companies in this sector are profiled in detail. For each of the top ten specialty pharma companies, this report provides a detailed examination of geographic and therapeutic focus, major currently marketed products and growth strategies in the form of key acquisitions and divestments. The opportunities and threats facing each of these leading players are also assessed. Discover the key trends and growth drivers of the specialty pharma market, compare the strategies and performance of the top ten companies and evaluate their future prospects with this new report. |
|
| Promotional activities within the pharma industry operate through various sales and promotional channels with the aim of convincing physicians, patients and payors about the value and efficacy of products. Return on investment (ROI) is the critical measure of success for such initiatives. However, a clear understanding of the ROI generated across various market and lifecycle settings is essential for companies attempting to optimize their detailing and journal advertising strategies in the future. ‘The Promotional Landscape in the US and Europe’ is a new report published by Business Insights that provides detailed strategic guidance for the preparation and execution of successful promotion strategies. This report examines a number of case studies of recent high profile promotional strategies and their associated sales data to provide a comprehensive analysis of the key success factors for detailing and journal advertising across various stages of the product lifecycle. The impact of market and product-level influences on promotional returns are assessed and the most effective methods of measuring promotional performance are also identified. Improve the effectiveness of your promotional strategies by examining the key factors affecting associated ROI and compare the promotional activities of leading companies with this report. |
|
| M&A activity in the pharma industry continues to gain momentum as a growing number of companies seek to replenish drug pipelines through biotechnology acquisitions. M&As between biotech companies are also growing in number, stimulated by the drive to strengthen product portfolios and expand participation in the growing global biotech market. Such deal activity is expected to become an increasingly prominent feature in the biotech sector over the next few years. Over 68% of respondents to Business Insights' recent proprietary survey carried out for this report believe that M&A initiatives will be integral to the continued success of their company. ‘Biotech M&A Trends: Deal assessments, trends and future prospects’ is a new report published by Business Insights that analyses trends in biotech M&A deals valued below $1bn across mid/small-sized pharma and biotech companies, including niche biopharma players and diagnostics/medical technology businesses. Trends in the value, volume and geographical distribution of deals are examined based on M&A activity since 2003 and a proprietary Business Insights survey reveals how over 130 industry executives perceive the future of biotech M&As. This report identifies the key factors influencing transactions with an evaluation of over 50 recent deals, in addition to providing a comprehensive case study analysis detailing the strategies behind five major M&A’s. |
|
| The dermatology market remains highly competitive, with developers ranging from Big Pharma to biotechnology and specialty pharmaceutical firms. In recent years levels of innovation in the area have dwindled, allowing generic competition to erode the market share of several leading brands across major drug classes. As leading players continue to lose ground to smaller, specialised players, opportunities are being created for companies that can implement effective lifecycle management and identify lucrative niches. ‘The Dermatology Market Outlook to 2013’ is a new report published by Business Insights that provides comprehensive coverage across key dermatology markets, with analysis of major currently marketed and pipeline drugs. The growth drivers and competitive dynamics of the area are assessed, with revenue and epidemiological forecasts provided for the period 2008-13. This report assesses the 10 leading companies in the dermatology market, examining their product portfolios and R&D pipelines to provide forecasts of their future competitive positions. This report also assesses prevalence rates across the seven major markets in addition to highlighting key trends across the global dermatology area, with coverage of over 95% of the total market. Discover the key trends and growth drivers of the market for dermatology treatments, assess the competitive dynamics of leading companies and evaluate the future prospects of major products. |
|
| In recent years, alliances between pharma and biotech companies have become common, with hundreds of relationships currently in place for drug developments across virtually all high priority conditions. Such alliances are of significant benefit to pharma companies who are aiming to combat the increasing need for new product development and rapidly escalating R&D costs. For biotechs, alliances provide crucial funding that can help to maintain and expand R&D activities. These synergistic benefits have resulted in over 30% of drugs in clinical trials now being a direct product of pharma-biotech alliances. However, poor deal structure and implementation continue to contribute to the failure of almost half of these relationships. ‘Successful Pharma-Biotech Alliance Strategies’ is a new report published by Business Insights that examines the current landscape for pharma-biotech alliances and provides an in-depth analysis of the underlying factors that can determine their success or failure. Recent major joint ventures, acquisitions and licensing deals are evaluated and the latest trends and developments affecting alliance management are assessed. This report also performs a detailed examination of 9 case studies that profile varying approaches to deal structuring and relationship management, in addition to charting the current and future alliance activities of the top ten pharmaceutical companies. Volume and value forecasts for pharma-biotech deals to 2015 are also provided. Improve the effectiveness of your alliance strategies with this report’s detailed examination of the key issues influencing the success of relationships and a case study analysis of major recent alliances. |
|
| The CNS disorders market is one of the largest and fastest growing markets in the pharmaceutical industry. Reimbursement terms continue to be favorable within the area, despite the relatively high risks associated with product development. This is largely due to significant levels of unmet medical need and the clinical specificity of many CNS drugs. High levels of investment have contributued to a rich product pipeline, with an estimated 600 clinical candidates currently under development, and companies are widely engaged in licensing novel/clinically differentiated CNS products. The sector has struggled recently however, with previously dominant product classes coming under increasing pressure from generic competition and safety concerns. ‘The CNS Market Outlook to 2013’ is a new report published by Business Insights that provides comprehensive coverage of the major markets within the global CNS disorders market, incorporating a detailed epidemiological analysis of major indications and key factors impacting their prevalence. This report profiles the factors and underlying trends shaping the market landscape and identifies the most promising areas of potential growth. Current leading brands of treatment within each indication are assessed and ten of the market’s leading players are profiled. Sales forecasts for currently marketed and key pipeline products over the 2008-13 period are also provided. Discover the key trends and growth drivers of the CNS market, assess the competitive dynamics of leading companies and evaluate the future prospects of pipeline products with this new report... |
|
 | Many pharma companies are currently engaged in wide-scale R&D restructuring, adopting a biotechnological approach to drug development by establishing disease-focused R&D units, R&D spin-offs, strategic partnerships and joint ventures. This trend has been reinforced by the emergence of public/private partnerships, co-operatives and open-source research initiatives that have encouraged companies to target previously neglected disease areas such as biotherapeutics and vaccines. Emerging markets are also driving change throughout R&D, with companies increasingly internationalizing their processes to take advantage of tax incentives, government investment, cheap labor and technology specialists. |
|
 | The market for respiratory disorder treatments is continuing to experience rapid expansion as healthcare payors increasingly acknowledge the high treatment costs associated with chronic indications. A shift in developmental focus has become the driving force for market transformation, with research efforts now targeting the causative disease pathway in an effort to prevent symptom presentation and pathological decline. In the short term, a number of impending product launches will satisfy unmet demand within high-value market niches by addressing issues of patient compliance and targeting patients at the more severe end of the disease spectrum. |
|
 | The Global Anti-infectives Market Outlook to 2013 provides comprehensive coverage of the anti-infectives market, incorporating the disease overview and detailed epidemiological analysis of the major indications. This report analyzes the marketed product portfolio, in-depth R&D pipeline analysis, market share data, sales forecast and the competitive landscape for the major players.August 2008 Format PDF |
|
 | The global generics market grew at a faster pace than the global pharma market in 2007, with a CAGR of 16.4% during 2004–2007. Regular patent expirations of blockbuster drugs are the primary growth driver of the industry.Rising healthcare expenditure has also contributed to industry expansion, with governments coming under growing pressure to provide low cost alternatives to branded drugs. However, the generics market is changing due to the threat from authorized generics, competition from players in emerging countries and increasing consolidation. Teva’s acquisition of Barr Pharmaceuticals is the latest example of companies attempting to improve their market strength and geographical reach via divestments and acquisitions. |
|
| Developing, manufacturing and marketing innovative new pharmaceutical drugs is highly complex and involves significant investment. Establishing an acceptable return on investment requires generating sufficient sales revenues which in turn requires maximizing market access at the highest possible price. |
|
| The rising prevalence of obesity is a growing problem in developed countries, with 32% of Americans and 17% of EU residents considered obese in 2008. The condition is associated with a range of severe co-morbidities, the most significant of which include asthma, cardiovascular disease, cancer, diabetes, hypertension and kidney disease. Obesity-related treatments cost healthcare payors billions of dollars each year, and the market for medications is steadily expanding as incidence of obesity continues to increase. Stringent regulations have restricted the amount of medications currently available, however many currently marketed products are failing to meet consumer needs. Obesity Drug Markets in the US and EU: Analysis of product pipelines and competitive environment is a new report published by Business Insights that explores the dynamics and drivers of the market for current and emerging obesity treatments. This report evaluates the performances and attributes of currently marketed products and highlights the most effective strategies for securing future success in this therapeutic area. The potential of leading obesity drug candidates is assessed and over 100 compounds are identified across pre-clinical, Phase I, Phase II and Phase III development. Forecasts of future sales are also provided, based upon trends in obesity drug usage, projected prevalence rates and the approval potential of emerging products. Explore the latest trends and innovations in obesity treatments, assess the performances of currently marketed medications and evaluate the potential of leading pipeline candidates with this report. |
|
 | Drug manufacture now typically accounts for 25% of company revenues and achieving agility in the manufacturing process has become essential for pharma companies hoping to align their supply chains with constant shifts in global product demand. In addition to offering efficiencies in cost, capacity and time-to-market, contract manufacturing organizations (CMOs) can provide innovative, state-of-the-art process and production technologies to support the rapid technical transfer of products from R&D to commercial manufacturing. However, the effective management of the CMO/sponsor relationship is critical not only in satisfying regulatory requirements amid growing concerns over quality control, but also in meeting the overall commercial aim of the project. ’Contract Manufacturing Strategies’ is a new report published by Business Insights that explores the future of the contract manufacturing market with a detailed analysis of emerging drivers and restraints, business models and production strategies. The potential benefits and risks of contract manufacturing are assessed and the key strategies for effective CMO selection and successful relationship management are identified. This report also reviews the latest FDA contract legislation to determine the most effective measures in ensuring regulatory compliance and assesses the rapidly expanding markets of India and China in terms of growth potential and regulatory outlook. Understand how the CMO market will develop over the 2008-13 period, identify emerging manufacturing strategies and regulatory developments and assess the outsourcing growth potential of India and China. |
|
| The pharmaceutical industry has recently endured intense speculation and negative publicity as a result of high profile product withdrawals caused by inadequate safety profiles. Regulatory bodies have responded swiftly; the FDA now requires mandatory surveillance data submission for drugs under increased scrutiny, and the EMEA is close to implementing similar strategies as part of drug policy harmonization initiatives for phase IV trials. |
|
| The costs associated with developing drugs have risen dramatically over the past decade and fewer drugs are obtaining regulatory approval. The pharmaceutical industry is continually exploring new ways of improving drug developments and one area of focus is adaptive clinical trial designs. These innovative clinical trial designs use accumulating data to guide potential modifications to the study as it progresses, without undermining the validity and integrity of the trial. The advantages of such designs include the reduced length and cost of clinical trials, lower patient numbers and the ability to stop a trial early where a drug has not shown efficacy. |
|
 | Business Intelligence for the Pharmaceutical IndustryBusiness Insights' portfolio of healthcare management reports is designed to help you make well informed and timely business decisions. We understand the problems facing today's pharmaceutical and healthcare executives when trying to drive your business forward, and appreciate the importance of accurate, up-to-date, incisive product, market and company analysis. We help you to crystallize your business decisions. |
|
| Leading Drug Delivery Companies and TechnologiesCompetitive landscape, company profiles and technological developmentsBusiness Intelligence for the Pharmaceutical IndustryBusiness Insights' portfolio of healthcare management reports is designed to help you make well informed and timely business decisions. We understand the problems facing today's pharmaceutical and healthcare executives when trying to drive your business forward, and appreciate the importance of accurate, up-to-date, incisive product, market and company analysis. We help you to crystallize your business decisions. |
|
 | In recent years, there have been concerted efforts to enhance the precision of disease diagnosis and monitoring as the hetrogeneity of conditions becomes increasingly understood. Targeting broad patient populations in a ‘one-pill-fits-all’ approach has begun to attract criticism, with the average efficacy of such drugs being estimated at 50% or less. In the current climate, biomarkers have emerged as key tools in the realisation of personalised medicine by characterizing specific diseases and treatment responses at the DNA, RNA, protein, or metabolite level. |
|
| Drug safety has become a major industry concern following the market withdrawal of Merck’s Vioxx in 2004 and several other discontinuations of COX-2 inhibitors. Although adverse reactions were previously considered a relatively minor risk compared to a drug’s wider benefit, both newly approved and established drugs are now under intense scrutiny. Drug approvals in the US and Europe have become subject to approval delays, rising requests for further clinical data, and greater chances of rejection. Regulators are currently attempting to reconfigure review processes in order to minimize delays in recognition of the potential mass benefits of new applications Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response is a new report published by Business Insights that provides a comprehensive review of current drug approval trends in the US and Europe with case studies highlighting successful and unsuccessful applications. Emerging regulatory developments and process improvements are examined and the strategic measures implemented by developers to enhance the approval potential of their drugs are assessed. This report also evaluates the future regulatory landscapes of the FDA and EMEA, with a review of anticipated developments through to 2012. Understand the changing landscape for FDA and EMEA drug approvals, discover the implications of process overhauls upon your drug applications and anticipate future regulatory developments with this new report. |
|
| In recent years, the biopharmaceutical industry has emerged as one of the most important sectors in the Healthcare industry. Advances in life sciences have resulted in the drug discovery process becoming more science-intensive, with an increasing emphasis cross-company collaborations and the exchange of information. However, growing commercial pressures and rising R&D costs have prompted many biotech companies to seek financial support from global Big Pharma corporations through licensing and collaborative R&D deals. Progressive enhancements in integration have subsequently led to traditional pharma companies becoming increasingly dependant upon the technology platforms and approaches adopted by biotech companies. The Fastest Growing Biopharmaceutical Companies: Growth strategies, comparative analysis and company profiles is a new report published by Business Insights that examines the structure and organization of the biopharmaceutical industry with a detailed analysis of the fastest growing biopharmaceutical companies. This report provides a comparative analysis of growth strategies and reviews the methods used to improve operational efficiency in light of cost pressures, generic competition, complex pricing, regulations, and globalization. This report also explores the levels of interaction and integration between biopharma companies and the wider pharma industry. Use key indicators to assess the performances of the fastest growing biopharma companies, benchmark their most successful strategies and understand major industrial issues with this new report. |
|
| During the last fifteen years tremendous advances have been made in deciphering the genetic coding of a variety of species from invertebrates, vertebrates and finally man through the formal initiation of the Human Genome Project in October 2000 and its completion in 2003. This information has helped to increase our understanding of how genetics has a pivotal role in the predisposition of many diseased states, the progression of a course of a disease, as well as a patient’s response to a drug, or lack of it. Now in the 21st Century there is a growing trend towards the development of personalized medicine – the right drug for the right individual. |
|
| In recent years, the maximization of blockbuster revenues has been compromised by generic price erosion and a decline in new drug approvals. Large pharmaceutical companies are coming under pressure to explore new R&D strategies and implement more cost-effective sourcing methods for innovative new molecules. The biotechnology industry is emerging as a hub of innovation for biomarker and new chemical entity (NCE) identification, and has become a vital component in the preclinical development of new drug technologies. As therapy focus shifts to treating the causal pathway of disease and not merely the symptomology, the majority of emerging targeted therapeutics are large molecule biologics, while monoclonal antibody therapies represents the fastest growing segment within the pharmaceutical industry. |
|
| The heart health food and drinks market has seen continued development and a generation of products targeting specific conditions such as blood pressure and cholesterol reduction, have been the focus of innovation. However, the market is beginning to shift again, this time towards more ‘natural’ heart health products which promote an overall, holistic and everyday approach to heart health. Heart Health Food and Drinks is a new management report published by Business Insights that analyzes the underlying growth drivers for the heart health foods and drinks market, assesses future sales prospects in key geographical markets, reviews the latest innovations trends and offers actionable recommendations for food and drinks manufacturers. It examines the latest actual and forecast data for hypertension and cardiovascular disease prevalence, heart health food and drinks sales values, as well as unique data on product innovations for all the key product groups. Develop more effective strategies for heart healthy food and drinks using this report’s analysis of the development of the market by country and product category. |
|
| Nanotechnologies have already attracted over $3bn of global government funding as part of efforts to enhance a range of disciplines including pharmaceuticals, drug delivery and healthcare monitoring. Advances in nanomaterials, nanostructures and nanosystems are expected to drive the value of the global nanotehnology market to over a trillion dollars by 2015, but many companies are remaining cautious, preferring to monitor developments in academia prior to making substantial investments. Despite such trepidation, the pharma industry is beginning to adopt nanotools throughout the R&D process to facilitate the high throughput screening of drug repositories, the identification of new drug targets and biomarkers for preclinical and clinical studies and the development of diagnostics and imaging agents. ‘Nanotechnology’ is a new report published by Business Insights that provides a comprehensive review of nanotechnology and it’s role in the development of next-generation nanomedicines. The nanotools and detection systems currently driving nanotechnology are profiled and the applications of nanotechnologies within the R&D process are assessed. This report measures the impact of nanotechnologies currently being applied to target cancer, cardiovascular disease and CNS disorders and also explores the implementation strategies of leading pharmaceutical, healthcare and nanotechnology start-ups. Use this new report to assess the future of nanotechnology within pharma R&D, identify the innovations driving growth within the market and examine the implementation strategies of leading companies. |
|
| R&D laboratories are co-ordinating the analysis of increasing volumes of disparate biological data, largely comprised of gene and protein sequences. Bioinformatics-enabled data management has enabled companies to improve productivity within their R&D programmes by identifying new drug targets, diagnostic biomarkers and biomarkers of drug efficacy and toxicity. From a systems biology approach, bioinformatics combine data into interactive models to highlight disease pathways and aid the discovery of on off-target effects of compounds. Knowledge management solutions are crucial in both instances, enabling project teams to make informed decisions about potential new drugs. ‘Innovations in Bioinformatics’ is a new report published by Business Insights that provides a detailed analysis of bioinformatic developments and applications. This report examines the bioinformatic tools used to manage high-throughput data from omic technologies, systems biology modelling and biomarker discovery. Knowledge management solutions are reviewed and the provisions of major bioinformatics contributors are highlighted. This report also provides forecasts for bioinformatic tools and services to 2011. Use this new report to identify the latest developments in bioinformatics, assess the tools and platforms that can improve drug developments and benchmark effective implementation strategies. |
|
| The cardiovascular therapeutic area has historically provided the largest single source of revenue for the pharmaceutical industry. The outlook for the market remains robust, driven by high patient populations and a widespread focus on preventative treatment. However, low growth rates in established indications will prevail due to the growing availability of effective generic medicines and an overall scarcity of innovative new drug launches. With product launches in mainstream cardiovascular indications facing continued difficulties, major pharma companies are now primarily focusing efforts upon compliance and protection against the generic threats posed by line extensions and combination treatments. Changes in the competitive positions of leading companies will become inevitable as new revenue sources continue to decline and established portfolios underperform. The Cardiovascular Market Outlook to 2012 is a new report published by Business Insights that provides comprehensive coverage of every class of drugs across all major cardiovascular indications. Detailed insights into recent key events and future market leaders are also provided, in addition to epidemiological analysis and forecasts for major products over the period 2007-12. With coverage of over 90% of the total market for cardiovascular products, this report profiles the underlying trends and factors driving the market and identifies the most promising areas of potential growth. Discover the key market trends and growth drivers of the cardiovascular market, assess the competitive dynamics of leading companies and evaluate the future prospects of major products with this new report... |
|
| Combination pharmaceutical products, or fixed-dose combinations (FDC’s), offer benefits to many drug classes due to the additive nature of therapeutic effect and the reduced level of side-effects associated with their use. Their core advantage however is an improvement in convenience that stems from reducing prescription numbers and their associated administrative costs. |
|
| Medicines in the cancer therapeutic area account for the third largest source of revenue within the pharma industry. The cancer market has experienced significant innovative change in recent years, creating attractive opportunities for a range of new and established biotechnology players as well as established pharma companies. Although new product development continues to involve substantial levels of risk, innovation is the key driving force in the market, and has led to the competitive exclusion of several of the industry’s traditional competitors. With successful launches now being applied to multiple indications faster than ever before, subsequent increases in product sales volumes are rapidly changing the competitive landscape of the cancer market. The Cancer Market Outlook to 2012 is a new report published by Business Insights that provides comprehensive coverage of the major markets in the global cancer area, incorporating a detailed epidemiological analysis of the nine major indications and key factors impacting their prevalence. Current leading brands of treatment within each cancer indication are analysed and eight of the market’s leading players are profiled. With coverage of over 9 % of the total market for cancer products, this report profiles the factors and underlying trends that are driving market transformation and identifies the most promising areas of potential growth. Forecasts for currently marketed and key pipeline products over the 2 6-12 period are also provided. Discover the key market trends and growth drivers of the cancer market, assess the competitive dynamics of leading pharma companies and evaluate the future prospects of major products with this new report.Published: January 2008 - Global. |
|
| The market for lifestyle drugs has become one of the most dynamic and commercially attractive sectors in the pharmaceutical industry. With developed markets expected to witness aging demographics as well as continued increases in health awareness, disposable incomes and pharmaceutical branding activity, conditions appear highly favourable for further growth. ‘Lifestyle Drugs Market Outlook’ is a new report published by Business Insights that provides a detailed analysis of seven individual lifestyle drug markets through the stages of drug delivery and discovery to product launch and lifecycle management. Key industrial trends in the fields of consumer demand and pipeline development are examined, leading players and products within each treatment area are profiled and the market potential of each lifestyle therapy is assessed. This report will also provide a substantial review of reimbursement policies within the seven major markets and their impact upon product sales. |
|
| Business Insights' portfolio of pharmaceutical outsourcing management reports are designed to help you make well informed and timely business decisions. We understand the problems facing today's pharmaceutical and healthcare executives when trying to drive your business forward, and appreciate the importance of accurate, up-to-date, incisive product, market and company analysis. We help you to crystallize your business decisions. The strength of our research and analysis is derived from access to unparalleled databases and libraries of information and the use of proprietary analytic techniques. |
|
| The modulation of immune system activity is a required pharmacological intervention for many medical conditions, bearing particular importance in the treatment of autoimmune diseases and allergies and transplant procedures. With traditional immunomodulatory drugs continuing to exhibit limited efficacy and adverse side effects, the drive to develop new, improved, and specifically targeted immunotherapies has been gaining momentum. |
|
| Drug developments in the US and EU are becoming increasingly expensive and time consuming, with new products typically requiring investment of over 4 years and $1billion from concept to commercialization. As a result, China has emerged as an increasingly attractive option for companies aiming to reduce such prohibitive investments in time and finance. Human clinical studies have historically dominated outsourced R&D activities in China, with the country’s relative lack of capital and expertise being insufficient to facilitate technologically intensive discovery and pre-clinical work. |
|
| As the pharma industry continues to experience rising research costs, drug failures and low returns on investment, companies who are increasingly facing major patent expiries and scarcely populated late-stage pipelines have accelerated efforts to enhance the speed and efficiency of drug research. Translational science has emerged as a concept that is set to revolutionise the traditional R&D paradigm by integrating drug discovery and development, areas with previously limited interaction. |
|
| The contract biomanufacturing market achieved a value of $2.5bn in 2006, with growth expected to continue at an annual rate of 0- 5% until at least 20. The proportion of biologics in new drug approvals has risen by over 30% during the last decade, and with the current pipeline containing more than 500 protein and 50 peptide developmental drugs, this trend is set to continue. The commercial success of over 350 approved biologics has prompted the biotechnology industry to accelerate discoveries in further protein-based therapeutics, placing greater emphasis upon the importance of biomanufacturing. Many biotechnology companies are faced with limited resources, and as large-scale manufacturing continues to intensify, deciding whether it should be internalised or outsourced to partners or CMO’s is increasingly crucial in the development of a biotech firm. |
|
| RNAi-based screens have provided new opportunities for the discovery and validation of novel therapeutic targets in areas such as cancer and infectious diseases. Since 2005, enormous strides have also been made in the development of RNAi-based therapeutic products, bringing them significantly closer to the market.‘Outlook for RNAi 2007’ is a new report which provides a detailed insight into the most effective use of this novel technology in the drug discovery and development process. It puts into context where RNAi technology is being used as a tool of choice within academia and the pharma industry for functional genomic studies, drug target discovery and mechanism of action studies. The development status RNAi based therapeutics is covered in detail, highlighting the key companies in the field, outlining their pipelines and describing the results of completed clinical trials. |
|
| The global pharmaceutical pricing and reimbursement environment is notoriously complex and continuously changing. Pharma companies must implement strategic pricing assessments across global markets and product lifecycle phases in order to develop effective pricing policies. By incorporating such assessments into portfolio evaluations and lifecycle planning, companies can enhance their understanding of potential price profiles for individual drugs and optimise future returns. |
|
| As the GIT Market begins to feature increasingly high levels of generic competition, the focus of pharmaceutical R&D strategies has shifted towards new therapy areas such as Crohn’s disease and Irritable Bowel Syndrome (IBS). Although such shifts are becoming the driving force for market transformation, growth rates may remain low due to the increased availability of effective generic medicines and fewer launches of innovative new drugs. |
|
| CNS disorders constitute one of the most significant components of healthcare spending in the developed world, contributing to an estimated 35% of the disease burden within the seven major pharma markets. However, an increased presence of generic products and lack of innovative product launches have prompted a slowdown in market growth, which pharma and biotech companies are addressing through a shift in R&D focus towards disease areas with relatively low levels of innovation, such as Alzheimer’s and Parkinson’s disease. |
|
| The growth of emerging pharmaceutical markets remains impressively buoyant, having attained a 14.7% value increase over the 2005-06 period, a substantially greater rate than those witnessed within the developed markets of the EU and US. Although emergent markets proffer access to sizeable patient populations, significant barriers to entry continue to exist. |
|
| Despite significant advances in prevention and treatment, cardiovascular disease remains the leading cause of death in economically advanced countries. The developing world has also begun to experience a disconcerting growth in prevalence, where the insurgence of CVD has exacerbated the risk factors associated with indigenous communicable diseases. Keeping pace with epidemiological change in both the developed and developing world constitutes the overriding challenge for industrial players, and involves successfully integrating into localised healthcare systems and reimbursement structures, in addition to remaining aligned with product demand. In the medical device, pharmaceutical and biotechnology industries, this challenge is being met with a focus on products that reduce adverse effects, improve patient outcomes and extend the range of formulations for existing indications. ‘Innovations in Cardiovascular Disease Management’ is a new report published by Business Insights that will examine the major developments shaping the future of the cardiovascular industry. This report will analyse the future potential of new and emerging products from the medical device, pharmaceutical and biotechnology sectors, and measure their likely impact upon the existing market. The extent to which these products can stimulate the growth and development of the future market will also be assessed. Use this report to evaluate the potential of new and emerging products in the treatment of cardiovascular diseases, assess the strength of competitor pipelines and identify future market opportunities. |
|
| Biotechnological products are continuing to exhibit substantial revenue gains, with the top 12 biologics registering sales growth of 20%in 2006, amassing a market share of $64 billion. However, the impending patent expiry of many leading products has created a number of highly attractive market opportunities for biosimilars. To exploit this significant potential, a complex route to market must first be negotiated, including numerous barriers to entry and regulatory hurdles. Prominent obstacles include the sizeable investments in time and expertise associated with biosimilars development, in addition to the fundamentally higher levels of cost and risk incurred by manufacturers. Legislative restraints in the US and a recently established regulatory framework in the EU have also contributed to industrial obtrusiveness, but for those developers who persevere, biosimilars are set to offer lucrative returns. The Future of Biosimilars: Key opportunities and emerging therapies is a new report published by Business Insights, examining the current market and regulatory environment for biosimilars in Europe, India, China and the US, whilst identifying the trends that will shape future market development. |
|
| Autoimmune related disorders continue to maintain prominence within the global disease burden, having achieved a worldwide market growth of 9.4% over the 2002-06 period. However, the inherent threat of generic competition and novel product launches are forecast to transform the dynamics of the autoimmune market over the next 5 years. The autoimmune pipeline represents a key opportunity for drug development companies, with the potential for success largely attributable to substantial unmet demand, a significant patient population and the medical proclivity for long term treatments. In consequence, the effective exploitation of market potential is becoming increasingly crucial, and hinges upon drug developments that accurately reflect the shifting demographics of autoimmune disorders and unmet patient needs. Autoimmune Market Outlook to 2012 is a new report published by Business Insights, examining how the competitive dynamics of major pharma companies will influence the market positions of products and shape the direction of future global autoimmunology. Market trends and leading brands of treatment are extensively profiled, while the most commercially promising R&D therapies are investigated and assessed to discover their sales potential. This report will also provide a comprehensive epidemiological analysis of the major indications and detailed product sales forecasts. Use this report to identify opportunities in the autoimmune pipeline, assess the dynamics of leading competitors and evaluate the impact of key trends across the global market. |
|
| In a market environment where competition from generics companies is becoming increasingly aggressive, and the patenting of therapeutics is continually subject to impending legislative change, understanding how to effectively reassess, develop and exploit patent protection strategies is essential in facilitating enhanced market exclusivity and revenue returns over the lifecycles of new drugs. Patent Protection Strategies: Maximising product revenues is a new report published by Business Insights that examines the need for optimising and sustaining the patent protection of novel products. The best methods of exploiting legislation to maximise revenue generation and protecting the considerable investments associated with innovations are also explored. It will also investigate both the offensive and defensive tactics that can develop product lifecycle strategies, through the refinery of organisational patent protection in tandem to encumbering the market entry of generic substitutes. Develop and apply successful patent protection strategies, exploit legislation effectively and secure the lifecycles of your innovations with this new report |
|
| Shifting epidemiological demographics within the HIV marketplace, increasing resistance to current therapies and unmet needs within the patient population...only an intrinsic understanding of these issues can secure the commercial success of new drug developments. ‘The Global HIV/AIDS Market Outlook to 2012’ is a new management report published by Business Insights that provides comprehensive coverage of the global HIV/AIDS market, incorporating a detailed epidemiological analysis of the prevalence of HIV/AIDS and key factors impacting prevalence in both the seven major pharmaceutical markets as well as emerging markets. This report analyses current leading brands of treatment within the HIV market, provides invaluable insights into market dynamics, profiles the leading pharmaceutical companies and details the key market trends influencing product sales. This new report will enable you to plan more effectively, evaluate key changes in the competitive landscape and identify potential growth areas in the global HIV/AIDS market. |
|
| Report overview Key findingsDrug repositioning is regarded as the pharma industry’s solution to falling R&D productivity and weakening product pipelines, successful repositioned drugs such as raloxifene (Evista; Lilly), thalidomide (Thalomid; Celegene), (Exubera;Pfizer/Nektar) have enabledinnovative companies to adopt lower risk strategies to optimize product pipelines. Drug Repositioning Strategies is a new report that provides in-depth analysis of leading pharma companies that are using novel technologies to reposition failed, marketed or reformulated compounds. This report analyzes strategies that are currently being employed by the leading players and the associated opportunities and challenges arising from them, enabling you to understand trends in the market and optimize your R&D pipeline. Use this report to examine current approaches to drug repositioning and identify successful technologies and business models that can help your organization deliver enhanced clinical and commercial output. |
|
| The highly dynamic cancer market is creating a new age of discovery and innovation driven by molecular biology, oncogenomics and new methods in cell biology. Resultantly, cancer innovatives are not only the fastest growing segment within the cancer market, but the key drivers of sales growth across the pharmaceutical market as a whole. |
|
| Traditionally, the Indian pharmaceutical industry has been characterized by a core competency in generics’ manufacturing and relatively immature capabilities in R&D. This outlook has evolved substantially since the 1990s and Indian companies have been making investments towards expanding drug discovery and development capabilities. The acceptance of patent laws and the rise of contract manufacturing have led to the diversification of revenue streams, enabling Indian pharma companies to experience high market growth. |
|
| The anti-infectives market is forecast to expand at a CAGR of 4.8%over the period 2005-11, driven largely by gains in the anti-bacterial and anti-viral classes. This represents significant market opportunity for pharma companies to expand their sales potential by targeting high growth markets. ‘The Global Anti-Infectives Market Outlook to 2011’ provides comprehensive coverage of the anti-infectives market, incorporating a detailed epidemiological analysis of the major indications and the key factors impacting their prevalence. Analysis of the major brands and profiles of the leading pharmaceutical companies will ensure that you can plan effectively, evaluate key changes in the competitive landscape, and identify potential growth areas within the global anti-infectives market. Use this report to assess anti-infective therapies that will be crucial to maintaining positive sales growth, analyze the marketed product portfolio and R&D pipelines of the leading 10 pharmaceutical companies in the global anti-infectives market. |
|
| With increased pricing pressure from generics, limited differentiation among new medicines and pipeline products and declining sales growth, the women’s health market is facing threatening competitive forces, prompting major pharmaceutical players to initiate key strategic changes. ‘The Women’s Health Market Outlook to 2011’ is a new report providing analysis of the current and future market for women’s health drugs across all major indications. Forecasts are given based on current marketed portfolio, drivers and resistors of growth and R&D pipelines, enabling you to predict changes in the dynamics of the global women’s health market. Key indications covered in this report are osteoporosis, infertility, uterine fibroids, endometriosis, urinary incontinence and gynecological infections. |
|
| With pharmaceutical R&D continuing to suffer from declining productivity levels and stagnant returns on investment, effective, flexible and commercially successful new product launches have become more important than ever. How pharma companies drive product uptake and the effectiveness of their competitive positioning during the launch phase increasingly define pharmaceutical market success. ‘Winning Product Launch Strategies’ is a new report featuring case studies of successful product launches of several key drugs. The results of 163 new product approvals and launches conducted across the US and EU are analyzed to provide up-to-date information on trends in new drug launches along with key factors for successful launches. Use this report to gain a comprehensive understanding of current and future product launch strategies, discover key differences between US and EU approaches and identify current best practices for successful product launch. |
|
